Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds Post published:October 20, 2020 Post category:Press Release
Havn Announces Appointments of Vic Neufeld and Rick Brar to Board; Accelerates Warrants Post published:October 5, 2020 Post category:Press Release
Havn Life Sciences Granted Section 56 Exemption to Begin Scientific Work With Psilocybin Post published:September 10, 2020 Post category:Press Release
Psychedelics Company Havn Life Announces Commencement of Public Trading on the CSE Post published:September 8, 2020 Post category:Press Release
Havn Life Sciences Announces Filing of Final Prospectus and Conditional Approval for Listing on CSE Post published:September 3, 2020 Post category:Press Release
Havn Life Sciences Inc. Announces Appointment of Gary Leong as Chief Science Officer Post published:July 6, 2020 Post category:Press Release
Havn Life Sciences Inc. Announces Launch & Filing of Preliminary Prospectus Post published:June 25, 2020 Post category:Press Release